The latest in transcatheter cardiovascular therapeutics and innovation from TCT 2017

Share

The Cardiovascular Research Foundation’s annual TCT conference serves as the premier cardiovascular event of the year: delivering the latest clinical and preclinical updates on a wide spectrum of transcatheter therapies. The 2017 edition was no exception. This was the second year that GCMI and T3 Labs has had a booth during TCT, and we stand behind the investment! Many walked by and stopped to have conversations surrounding the ever evolving transcatheter cardiovascular innovation space.

It is safe to speak for all in attendance when saying #TCTDenver was a high value event.

If cardiology is your focus or strength, TCT is a must attend. This year, we were fortunate to catch up with past and current T3 Labs sponsors as well as a handful of medical device companies that we look forward to partnering within the next year.

From the FDA town halls and innovation sessions to unique live cases, all levels of product development and use were on display. While there were plenty of learning opportunities for the primary physician audience, there was plenty of knowledge passed back and forth among engineers, physicians and training personnel regarding established and new device use.

Here are a few key takeaways from sessions attended:

  • Coronary imaging techniques vary and each have pros/cons:  IVUS, OCT, FFR, angiography.
  • Difficulties in ventricular septal defect cases includes placing guidewire through the defect in wall.
  • Drivers for imaging choices include minimizing contrast delivery to patients.
  • Patients do not want to be on drugs – if a one-time higher risk procedure is available, they will choose the procedure over the drug.
  • Blood pressure measurement variability is a challenge – measurement methods do not match, and blood pressure fluctuates considerably for one person
  • Studies in renal denervation are still lacking good control data to show effects on hypertension

GCMI and T3 Labs is a one-stop-shop for cardiologists and other medical product entrepreneurs and development teams.

If you are evaluating the viability of a novel medical device or product for the cardiovascular/thoracic market, are ready for preclinical testing, or seeking the best bioskills training for your physicians, surgeons or sales teams, T3 Labs is a full service CRO that provides an efficient experience for preclinical testing and training. We are committed to excellence in every facet of translational research, including cardiology. This is why industry leaders like Abbott Vascular, CardioMEMS, ALung Technologies, CorAmi and dozens of others rely on T3 Labs for their preclinical testing and training needs.

“At T3 Labs they have the perfect setup for what we needed,” says Dr. Rebecca Levit, Chief Scientific Officer of CorAmi Therapeutics. “From the cath lab to fluoroscopy to large animal proficiency, not to mention years of expertise specific to cardiology.”

If you are a physician innovator with a ‘back of the napkin’ idea for a new cardiovascular/thoracic device, a medical device company of any shape or size evaluating a new product’s readiness for preclinical testing, we want to know you! Contact us to learn how T3 Labs’ industry leading preclinical CRO scientists can be your trusted preclinical partner.or learn more about how GCMI’s D2 team can streamline your product’s development. Until we reconvene at TCT 2018, follow along with GCMI and T3 Labs on both Linkedin and twitter, and click here to receive our monthly medtech newsletter.